Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.
Pasireotide in the treatment of neuroendocrine tumors: A review of the literature / G. Vitale, A. Dicitore, C. Sciammarella, S. Di Molfetta, M. Rubino, A. Faggiano, A. Colao. - In: ENDOCRINE-RELATED CANCER. - ISSN 1351-0088. - 25:6(2018 Jun), pp. R351-R364.
Pasireotide in the treatment of neuroendocrine tumors: A review of the literature
G. Vitale
Primo
;A. DicitoreSecondo
;
2018
Abstract
Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.File | Dimensione | Formato | |
---|---|---|---|
ERC2018.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.34 MB
Formato
Adobe PDF
|
1.34 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.